Performance characteristics of the TRUGENE HIV-1 Genotyping Kit and the OpenGene DNA Sequencing System

Journal of Clinical Microbiology

Volumn 41, Issue 4, 2003, Pages 1594-1599

  Kuritzkes, Daniel R ^a,g   Grant, Robert M ^b   Feorino, Paul ^d   Griswold, Marshal ^c   Hoover, Marie ^e   Young, Russell ^a   Day, Stephen ^d   Lloyd Jr , Robert M ^d   Reid, Caroline ^f   Morgan, Gillian F ^f   Winslow, Dean L ^f  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b GLADSTONE INSTITUTE OF VIROLOGY AND IMMUNOLOGY   (United States)

^c State of Virginia's Division   (United States)

^d Visible Genetics Inc   (United States)

^e Advanced BioMedical Laboratories   (United States)

^f Visible Genetics Inc   (Canada)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID CITRATE DEXTROSE; ANTICOAGULANT AGENT; ANTIRETROVIRUS AGENT; BILIRUBIN; EDETIC ACID; HEMOGLOBIN; PROTEINASE; RNA DIRECTED DNA POLYMERASE; TRIACYLGLYCEROL;

ACCURACY; ARTICLE; BIOASSAY; CONTROLLED STUDY; CYTOMEGALOVIRUS; DNA SEQUENCE; DRUG RESISTANCE; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS 2; INTERMETHOD COMPARISON; MOLECULAR CLONING; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RNA EXTRACTION; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; VIRUS GENE; VIRUS MUTATION;

ANTICOAGULANTS; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; REAGENT KITS, DIAGNOSTIC; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; SPECIMEN HANDLING;

CYTOMEGALOVIRUS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMAN T-LYMPHOTROPIC VIRUS 2; RNA VIRUSES;

EID: 12444321945     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.41.4.1594-1599.2003     Document Type: Article

References (17)

1. Baxter, J. D., D. L. Mayers, D. N. Wentworth, J. D. Neaton, M. L. Hoover, M. A. Winters, S. B. Mannheimer, M. A. Thompson, D. I. Abrams, B. J. Brizz, J. P. A. Ioannidis, T. C. Merigan, and the CPCRA 046 Study Team for the Terry Berin Community Programs for Clinical Research on AIDS (CP-CRA). 2000. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. AIDS 14:F83-F93.
2. Cohen, C. J., M. Sension, C. Farthing, M. Conant, S. Jacobson, J. Nadler, W. Verbiest, K. Hertogs, M. Ames, A. Rinehart, N. M. Graham, and the VIRA 3001 Study Team. 2002. A randomized trial assessing the Impact of phenotypic resistance testing on antiretroviral therapy. AIDS 16:1-10.
3. D'Aquila, R. T., V. A. Johnson, S. L. Welles, A. J. Japour, D. R. Kuritzkes, V. DeGruttola, P. S. Reichelderfer, R. W. Coombs, C. S. Crumpacker, J. O. Kahn, and D. D. Richman for the AIDS Clinical Trials Group 116B/117 Team, and the Virology Committee Resistance Working Group. 1995. Zidovudine resistance and human immunodeficiency virus type 1 disease progression during antiretroviral therapy. Ann. Intern. Med. 122:401-408.
4. Deeks, S. G., N. S. Hellmann, R. M. Grant, N. T. Parkin, C. J. Petropoulos, M. Becker, W. Symonds, M. Chesney, and P. A. Volberding. 1999. Novel four-drug salvage treatment regimens after failure of HIV-1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility. J. Infect. Dis. 179:1375-1381.
5. DeGruttola, V., L. Dix, R. D'Aquila, D. Holder, A. N. Phillips, M. AitKhaled, J. D. Baxter, P. Clevenbergh, S. Hammer, R. P. Harrigan, D. Katzenstein, R. Lanier, M. D. Miller, M. Para, S. Yerly, A. R. Zolopa, J. S. Murray, A. Patick, V. Miller, S. Castillo, L. Pedneault, and J. Mellors. 2000. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir. Ther. 5:41-48.
6. Dickover, R. E., S. A. Herman, K. Saddiq, D. Wafer, M. Dillon, and Y. J. Bryson. 1998. Optimization of specimen-handling procedures for accurate quantitation of levels of human immunodeficiency virus RNA in plasma by reverse transcriptase PCR. J. Clin. Microbiol. 36:1070-1073.
7. Durant, J., P. Clevenbergh, P. Halfon, P. Delgiudice, S. Porsin, P. Simonet, N. Montagne, C. A. B. Boucher, J. M. Schapiro, and P. Dellamonica. 1999. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomized controlled trial. Lancet 353:2195-2199.
8. The EuroGuidelines Group for HIV Resistance. 2001. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. AIDS 15:309-320.
9. Grant, R. M., D. R. Kuritzkes, V. Johnson, J. W. Mellors, J. L. Sullivan, R. Swanstrom, R. D'Aquila, M. Van Goder, M. Holodiny, R. M. Lloyd, Jr., C. Reid, G. Morgan, and D. L. Winslow. 2003. Accuracy of the TRUGENE HIV-1 Genotyping Kit. J. Clin. Microbiol. 41:1586-1593.
10. Hirsch, M. S., F. Brun-Vézinet, R. T. D'Aquila, S. M. Hammer, V. A. Johnson, D. R. Kuritzkes, C. Loveday, J. W. Mellors, B. Clotet, B. Conway, L. M. Demeter, S. Vella, D. M. Jacobsen, and D. D. Richman. 2000. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA 283:2417-2426.
11. Holodniy, M., S. Kim, D. Katzenstein, M. Konrad, E. Groves, and T. Merigan. 1991. Inhibition of human immunodeficiency virus gene amplification by heparin. J. Clin. Microbiol. 29:676-679.
12. Holodniy, M., L. Mole, B. Yen-Liebermen, D. Margolis, C. Starkey, R. Carroll, T. Spahlinger, J. Todd, and J. B. Jackson. 1995. Comparative stabilities of quantitative human immunodeficiency virus RNA in plasma from samples collected in VACUTAINER CPT, VACUTAINER PPT, and standard VACUTAINER tubes. J. Clin. Microbiol. 33:1562-1566.
13. Japour, A. J., S. Welles, R. T. D'Aquila, V. A. Johnson, D. D. Richman, R. W. Coombs, P. S. Reichelderfer, J. O. Kahn, C. S. Crumpacker, D. R. Kuritzkes, for the AIDS Clinical Trials Group 116B/117 Study Team, and the Virology Committee Resistance Working Group. 1995. Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients following long-term zidovudine treatment. J. Infect. Dis. 171:1172-1179.
14. Kozal, M. J., R. W. Shafer, M. A. Winters, D. A. Katzenstein, and T. C. Merigan. 1993. A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients. J. Infect. Dis. 167:526-532.
15. Little, S. J., E. S. Daar, R. T. D'Aquila, P. H. Keiser, E. Connick, J. M. Whitcomb, N. S. Hellmann, C. J. Petropoulos, L. Sutton, J. A. Pitt, E. S. Rosenberg, R. A. Koup, B. D. Walker, and D. D. Richman. 1999. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA 282:1142-1149.
16. Tural, C., L. Ruiz, C. Holtzer, J. Schapiro, P. Viciana, J. Gonzales, P. Domingo, C. Boucher, C. Rey-Joly, B. Clotet, and the HIV-Antigen Study Group. 2002. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS 16:209-218.
17. Zolopa, A. R., R. W. Shafer, A. Warford, J. G. Montoya, P. Hsu, D. Katzenstein, T. C. Merigan, and B. Efron. 1999. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Ann. Intern. Med. 131:813-821.